ATOSSA THERAPEUTICS, INC.: cashflow_financing
| Value | {"amount": 102428710, "concept": "us-gaap:NetCashProvidedByUsedInFinancingActivities", "currency": "USD"} |
|---|---|
| Period | 2021-01-01 – 2021-03-31 |
| Status | superseded |
| Entity | ATOSSA THERAPEUTICS, INC. |
Provenance
Source: SEC EDGAR CompanyFacts (US-PD-17USC105)
Reference:
Retrieved: 2026-08-19T14:48:01.895087+02:00
Raw response sha256:
Also addressable by official identifiers:
Cite as: FACTANKER, https://factanker.com/fact/de2f3334-a688-4b5a-a844-923bc703d1f3
Source: SEC EDGAR CompanyFacts (US-PD-17USC105)
Reference:
0001437749-21-012213 · Open the official SEC filing →Retrieved: 2026-08-19T14:48:01.895087+02:00
Raw response sha256:
f7bde1a401b286c74a2fd824ee1df541…Also addressable by official identifiers:
https://factanker.com/fact/sec/cik-0001488039/cashflow-financing/2021-03-31 (CIK, metric, reporting date)Cite as: FACTANKER, https://factanker.com/fact/de2f3334-a688-4b5a-a844-923bc703d1f3
History
- no predecessors — first report